Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency

Inclusion Criteria: * Patients aged 18 and up * Patients with maximum serum growth hormone concentration of less than 5 ng/ml * Patients who can successfully complete this study based on appropriate medical judgment or who expect to benefit from this study * Persons who have agreed in writing to participate in this study Exclusion Criteria: * Persons who are currently under treatment after being diagnosed with a malignant tumor * Hepatosis * Renal function disorder * Intra-cranial hypertension * Proliferative diabetic retinopathy * Persons who carry acromegaly activity * Fertile women who are not pregnant or who do not take appropriate contraceptive measures and whose urine tested positive for hCG (human Chorionic Gonadotropin) * Mental patients and/or drug addicts and alcoholics * Patients who had participated in the other drug study within the last 30 days prior to participating in this study * Patients considered unfit for this study by the attending physician